FDA has approved the trade name Firmagon for degarelix for injection, a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer. “This ...

WEST DRAYTON, England, 17 June, 2014 – Ferring Pharmaceuticals confirmed today that FIRMAGON® (degarelix) will be the subject of an appeal hearing by the National Institute for Health and Care ...

Ferring Pharmaceuticals, USA today received approval from the U.S. Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, ...

Degarelix, being injectable, frequently causes injection-site reactions, which affect up to 40% of patients. 8 These reactions often result in irritation and occasionally cause small bumps at the ...

CS21 was a three-arm, randomized (1:1:1), open-label, parallel-group Phase III trial of 12 months' duration incorporating adult male patients with histologically confirmed adenocarcinoma of the ...